NousQ Pte Ltd, a dynamic start-up based in Singapore, is thrilled to announce the successful closure of its Seed Round, raising over USD 1.2 million to further its mission of revolutionizing healthcare. Originally pivoting in July 2021, the company has dedicated itself to designing, developing, manufacturing, and commercializing patient-centric medical technology and devices that truly meet the needs of those seeking better care. This latest funding milestone is a testament to the confidence investors have in NousQ’s vision to optimize healthcare delivery for existing patients while also reaching the millions who currently face barriers to accessing quality care. With this substantial capital infusion, NousQ plans to accelerate the development and commercialization of its innovative product portfolio, including the much-anticipated Clikx device. The first-in-man pilot clinical trial for Clikx is set to commence in 2022 in Singapore, marking a significant step towards proving its safety and efficacy in a real-world clinical setting. Beyond technological advancement, the funding will empower NousQ to build robust partnerships with key stakeholders, fostering a sustainable enterprise dedicated to bringing hope and high-quality medical solutions to patients around the globe. As healthcare challenges evolve, NousQ Pte Ltd remains resolute in its drive to not only cater to current patient needs but also to pioneer accessible solutions for those underserved by traditional healthcare systems. This funding round is not just a financial boost—it symbolizes a collaborative leap towards a future where innovation meets compassion, ensuring that every patient, regardless of circumstance, has the opportunity to receive the care they deserve.

NousQ Pte Ltd Secures $1.2M Seed Round to Revolutionize Patient-Centric Medical Innovation
Get the full NousQ Pte Ltd company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Anveshan
We are a food-tech startup aiming to provide high quality deeply traceable food products. We leverage technologies based on image processing, spectroscopy, blockchain and IOT to provide the best quality food products made traditionally.
$12.7M Series b
today

Caseway
We are the only enterprise AI form platform that replaces internal R&D and manual workflows by building and maintaining fully integrated automation systems, aligned to your data, your processes, and your long-term success. For document-intensive, compliance-driven organizations in regulated industries like insurance, education, finance, healthcare, and government Compelling reason to buy: Who need AI and automation tailored to their unique forms, workflows, and security environment, without having to shoulder R&D risk or manage AI development internally Product category: Our product is an enterprise document form platform Key benefit: That delivers a fully integrated, continuously improving automation system, built and maintained by experts, without upfront AI build costs Key differentiation: Our product is custom-built for each client’s systems and documents, fully integrated and continuously improved through a long-term partnership model, we maintain, debug, adapt, and align incentives to make it work in the real world.
$1.5M Pre-seed
today

Kubera Health
Kubera’s mission is to power a payment ecosystem where contracts are honored, care is rewarded, and waste is eliminated. We deliver contract and payment intelligence that unifies policies, terms, and claims data into one trusted platform — helping healthcare organizations and their partners build fairer contracts, ensure payments flow as intended, and align incentives across the care ecosystem. As healthcare shifts toward new reimbursement models and risk-sharing arrangements, Kubera is building the payment-intelligence backbone that enables multiple parties to adapt faster, protect margins, and dedicate more resources to patient care.
$6.5M Seed
today

Psilera
Psilera is a biotechnology company founded by scientists dedicated to finding better therapeutics for neurological conditions like dementia, addiction, and mental health disorders. Since 2019, Psilera has been focused on early-stage drug discovery & development with a dynamic team of experts in synthetic chemistry, pharmacology, clinical development, and business development.
$8.8M Seed
today

Abstract
Abstract is a venture capital firm based in San Francisco with $1.5 billion in assets under management. We are sector-agnostic, focused on seed and early stage founders. Our reputation among founders is built on fierce loyalty, unparalleled connections, and a relentless drive to help them win.
$59.0M Series a
today
Other recent Seed rounds
Companies that recently closed a Seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | ![]() Kubera Health United States | Seed | $6.5M | today |
| 2 | ![]() Psilera United States | Seed | $8.8M | today |
| 3 | ![]() AlmaBetter India | Seed | $240.0K | today |
| 4 | ![]() CodeIntegrity United States | Seed | $5.0M | today |
| 5 | ![]() kopa.ai Lithuania | Seed | $2.3M | today |


